Faster drug approvals on the way as China welcomes foreign clinical data

The China Food and Drug Administration has announced far-reaching reforms to its regulatory system that are expected to speed up approvals of medical technologies in the country.

Most importantly, the changes mean that data from clinical trials conducted outside of the country will now be accepted as part of regulatory filings by the CFDA, Chinese press agency Xinhua has reported.

This is likely to result in a significant increase in the speed with which global drug developers are able to secure approval in China, as it will remove the need to conduct additional trials in the country.